1 | subgroup | 8,988 |
2 | mediation | 518 |
3 | moderator | 289 |
4 | sub-group | 280 |
5 | moderation | 207 |
6 | subsidiary | 83 |
7 | subcategory | 38 |
8 | time-of-day | 30 |
9 | time-trend | 11 |
10 | ccdss | 8 |
11 | age-subgroup | 6 |
12 | .subgroup | 5 |
13 | change-score | 5 |
14 | sub-category | 5 |
15 | mediator/moderator | 4 |
16 | meditational | 4 |
17 | lag-censoring | 3 |
18 | micro-xrd | 3 |
19 | q-scores | 3 |
20 | time-to-response | 3 |
21 | .multivariate | 2 |
22 | categorial | 2 |
23 | cdna-rapd | 2 |
24 | co-segregation | 2 |
25 | diet-by-time | 2 |
26 | dwell-time | 2 |
27 | force-plate | 2 |
28 | human-risk | 2 |
29 | igs-rflp | 2 |
30 | mm-ancova | 2 |
31 | non-intention-to-treat | 2 |
32 | re-execution | 2 |
33 | sibpair | 2 |
34 | vasoconstriction-volume | 2 |
35 | -matching | 1 |
36 | 2-cross-over | 1 |
37 | bi-rads-conform | 1 |
38 | binary-choice | 1 |
39 | breathe-5 | 1 |
40 | comparators.nine | 1 |
41 | completed-data | 1 |
42 | cophylogenetic | 1 |
43 | cost-threshold | 1 |
44 | cost-to-utility | 1 |
45 | cross-phase | 1 |
46 | cross-vendor | 1 |
47 | data-pooled | 1 |
48 | dbn-based | 1 |
49 | effect.limitation | 1 |
50 | effectsthe | 1 |
51 | g*power | 1 |
52 | growth-trajectory | 1 |
53 | hplc-esi-qtof | 1 |
54 | hpv-genotype | 1 |
55 | immunohistochemical/immunostaining | 1 |
56 | intentiontotreat | 1 |
57 | intervention-outcome | 1 |
58 | medication/a118g | 1 |
59 | medicine-effectiveness | 1 |
60 | model-variability | 1 |
61 | multi-test | 1 |
62 | multiple-failure-per-subject | 1 |
63 | multivaria-te | 1 |
64 | nonfinal | 1 |
65 | outcome.sensitivity | 1 |
66 | oversophisticated | 1 |
67 | placebo.cost-effectiveness | 1 |
68 | pmhcii-tetramer | 1 |
69 | pre-hoc | 1 |
70 | publication-bias | 1 |
71 | reports/secondary | 1 |
72 | scattershot | 1 |
73 | serobiochemical | 1 |
74 | statistically-controlled | 1 |
75 | time-cumulative | 1 |
76 | time-stability | 1 |
77 | treatment-interaction | 1 |
78 | tukey’s | 1 |
79 | working-posture | 1 |
80 | z-score-adjusted | 1 |
81 | χ₂ | 1 |
82 | •kaplan-meier | 1 |
1 | -matching | 1 |
2 | .multivariate | 2 |
3 | .subgroup | 5 |
4 | 2-cross-over | 1 |
5 | age-subgroup | 6 |
6 | bi-rads-conform | 1 |
7 | binary-choice | 1 |
8 | breathe-5 | 1 |
9 | categorial | 2 |
10 | ccdss | 8 |
11 | cdna-rapd | 2 |
12 | change-score | 5 |
13 | co-segregation | 2 |
14 | comparators.nine | 1 |
15 | completed-data | 1 |
16 | cophylogenetic | 1 |
17 | cost-threshold | 1 |
18 | cost-to-utility | 1 |
19 | cross-phase | 1 |
20 | cross-vendor | 1 |
21 | data-pooled | 1 |
22 | dbn-based | 1 |
23 | diet-by-time | 2 |
24 | dwell-time | 2 |
25 | effect.limitation | 1 |
26 | effectsthe | 1 |
27 | force-plate | 2 |
28 | g*power | 1 |
29 | growth-trajectory | 1 |
30 | hplc-esi-qtof | 1 |
31 | hpv-genotype | 1 |
32 | human-risk | 2 |
33 | igs-rflp | 2 |
34 | immunohistochemical/immunostaining | 1 |
35 | intentiontotreat | 1 |
36 | intervention-outcome | 1 |
37 | lag-censoring | 3 |
38 | mediation | 518 |
39 | mediator/moderator | 4 |
40 | medication/a118g | 1 |
41 | medicine-effectiveness | 1 |
42 | meditational | 4 |
43 | micro-xrd | 3 |
44 | mm-ancova | 2 |
45 | model-variability | 1 |
46 | moderation | 207 |
47 | moderator | 289 |
48 | multi-test | 1 |
49 | multiple-failure-per-subject | 1 |
50 | multivaria-te | 1 |
51 | non-intention-to-treat | 2 |
52 | nonfinal | 1 |
53 | outcome.sensitivity | 1 |
54 | oversophisticated | 1 |
55 | placebo.cost-effectiveness | 1 |
56 | pmhcii-tetramer | 1 |
57 | pre-hoc | 1 |
58 | publication-bias | 1 |
59 | q-scores | 3 |
60 | re-execution | 2 |
61 | reports/secondary | 1 |
62 | scattershot | 1 |
63 | serobiochemical | 1 |
64 | sibpair | 2 |
65 | statistically-controlled | 1 |
66 | sub-category | 5 |
67 | sub-group | 280 |
68 | subcategory | 38 |
69 | subgroup | 8,988 |
70 | subsidiary | 83 |
71 | time-cumulative | 1 |
72 | time-of-day | 30 |
73 | time-stability | 1 |
74 | time-to-response | 3 |
75 | time-trend | 11 |
76 | treatment-interaction | 1 |
77 | tukey’s | 1 |
78 | vasoconstriction-volume | 2 |
79 | working-posture | 1 |
80 | z-score-adjusted | 1 |
81 | χ₂ | 1 |
82 | •kaplan-meier | 1 |
1 | breathe-5 | 1 |
2 | completed-data | 1 |
3 | mm-ancova | 2 |
4 | cophylogenetic | 1 |
5 | pre-hoc | 1 |
6 | statistically-controlled | 1 |
7 | data-pooled | 1 |
8 | dbn-based | 1 |
9 | oversophisticated | 1 |
10 | z-score-adjusted | 1 |
11 | cost-threshold | 1 |
12 | time-trend | 11 |
13 | cdna-rapd | 2 |
14 | micro-xrd | 3 |
15 | binary-choice | 1 |
16 | effectsthe | 1 |
17 | dwell-time | 2 |
18 | diet-by-time | 2 |
19 | intervention-outcome | 1 |
20 | vasoconstriction-volume | 2 |
21 | comparators.nine | 1 |
22 | hpv-genotype | 1 |
23 | change-score | 5 |
24 | working-posture | 1 |
25 | cross-phase | 1 |
26 | time-to-response | 3 |
27 | multivaria-te | 1 |
28 | .multivariate | 2 |
29 | force-plate | 2 |
30 | time-cumulative | 1 |
31 | hplc-esi-qtof | 1 |
32 | medication/a118g | 1 |
33 | -matching | 1 |
34 | immunohistochemical/immunostaining | 1 |
35 | lag-censoring | 3 |
36 | human-risk | 2 |
37 | serobiochemical | 1 |
38 | categorial | 2 |
39 | nonfinal | 1 |
40 | meditational | 4 |
41 | bi-rads-conform | 1 |
42 | co-segregation | 2 |
43 | mediation | 518 |
44 | moderation | 207 |
45 | effect.limitation | 1 |
46 | treatment-interaction | 1 |
47 | re-execution | 2 |
48 | igs-rflp | 2 |
49 | sub-group | 280 |
50 | subgroup | 8,988 |
51 | age-subgroup | 6 |
52 | .subgroup | 5 |
53 | •kaplan-meier | 1 |
54 | pmhcii-tetramer | 1 |
55 | 2-cross-over | 1 |
56 | g*power | 1 |
57 | sibpair | 2 |
58 | cross-vendor | 1 |
59 | moderator | 289 |
60 | mediator/moderator | 4 |
61 | publication-bias | 1 |
62 | q-scores | 3 |
63 | ccdss | 8 |
64 | medicine-effectiveness | 1 |
65 | placebo.cost-effectiveness | 1 |
66 | tukey’s | 1 |
67 | non-intention-to-treat | 2 |
68 | intentiontotreat | 1 |
69 | multiple-failure-per-subject | 1 |
70 | scattershot | 1 |
71 | multi-test | 1 |
72 | time-of-day | 30 |
73 | reports/secondary | 1 |
74 | subsidiary | 83 |
75 | sub-category | 5 |
76 | subcategory | 38 |
77 | growth-trajectory | 1 |
78 | model-variability | 1 |
79 | time-stability | 1 |
80 | cost-to-utility | 1 |
81 | outcome.sensitivity | 1 |
82 | χ₂ | 1 |